Home › Pancreatic Cancer › North Carolina › Durham
Pancreatic Cancer clinical trials in Durham, NC
24 studies for Pancreatic Cancer are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
A Study of PHN-012 in Patients With Advanced Solid Tumors
RecruitingPhase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
RecruitingPhase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RecruitingPhase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi away
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingPhase 3
- Investigative Site US035, Chapel Hill · 10 mi away
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RecruitingPhase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RecruitingPhase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Recruiting
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
RecruitingObservational study
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi away
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi away
- University of North Carolina, Chapel Hill · 10 mi away
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
RecruitingPhase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RecruitingPhase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
RecruitingPhase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RecruitingPhase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
RecruitingPhase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
RecruitingPhase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RecruitingPhase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RecruitingPhase 2
- University of North Carolina, Chapel Hill · 10 mi away
About Pancreatic Cancer
The pancreas is a gland behind your stomach that produces insulin. Pancreatic cancer is hard to catch early. Find out about risk factors and symptoms.
More about Pancreatic Cancer on MedlinePlus
Pancreatic Cancer trials in other cities
- Houston, TX61 studies
- New York City, NY60 studies
- Boston, MA43 studies
- Nashville, TN39 studies
- Los Angeles, CA35 studies
- St. Louis, MO33 studies
- Arlington, VA33 studies
- Baltimore, MD31 studies
- San Antonio, TX31 studies
- Philadelphia, PA26 studies
- Tampa, FL26 studies
- San Diego, CA24 studies
Other studies in Durham
- Breast Cancer64 studies
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Lung Cancer32 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Chronic Lymphocytic Leukemia27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.